AstraZeneca collaborates with cancer research organisations to develop portfolio
This article was originally published in Scrip
AstraZeneca has signed agreements with two research organisations, Cancer Research UK (CRUK) and the US-based Sarah Cannon Research Institute, that will allow the company to develop its experimental oncology products. Although the mechanisms of the interactions are different, both deals mean that AstraZeneca can advance its experimental compounds without drawing unnecessarily on its internal resources.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.